Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2020-11-20 | APLT | Applied Therapeutics Inc. | Perfetti Riccardo | Chief Medical Officer | S - Sale+OE | $19.80 | -2,590 | 0 | -100% | -$51,290 | |||||
| M | 2020-11-23 | CORT | Corcept Therapeutics Inc | Baker G Leonard Jr | Dir | P - Purchase | $22.93 | +2,980 | 5,158,658 | 0% | +$68,328 | |||||
2020-11-23 | ABEO | Abeona Therapeutics Inc. | Wider Todd | Dir | S - Sale | $1.33 | -17,969 | 954,132 | -2% | -$23,981 | ||||||
| M | 2020-11-20 | ORGO | Organogenesis Holdings Inc. | Avista Capital Managing Member Iv, LLC | Dir, 10% | P - Purchase | $4.99 | +2,839 | 29,924,515 | 0% | +$14,171 | |||||
2020-11-23 | CHMA | Chiasma, Inc | Kannan Raj | CEO | P - Purchase | $4.00 | +120,000 | 137,095 | +702% | +$480,492 | ||||||
| A | 2020-11-19 | CARA | Cara Therapeutics, Inc. | Ives Jeffrey L. | Dir | S - Sale | $15.75 | -2,500 | 10,700 | -19% | -$39,373 | |||||
2020-11-20 | ABBV | Abbvie Inc. | Gosebruch Henry O | EVP, Chief Strategy Officer | S - Sale | $99.38 | -40,000 | 124,476 | -24% | -$3,975,046 | ||||||
| M | 2020-11-20 | MATN | Mateon Therapeutics Inc | Shah Amit B. | CFO | P - Purchase | $0.19 | +60,000 | 60,000 | New | +$11,558 | |||||
2020-11-23 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $0.93 | -20,000 | 25,098,546 | 0% | -$18,626 | ||||||
2020-11-24 | CLSD | Clearside Biomedical, Inc. | Whitmore Bradford T | 10% | P - Purchase | $1.65 | +62,000 | 5,909,341 | +1% | +$102,046 | ||||||
| D | 2020-11-24 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $1.60 | +625,000 | 35,356,212 | +2% | +$1,000,000 | |||||
| D | 2020-11-23 | SDGR | Schrodinger, Inc. | Lebowitz Joel | See Remarks | S - Sale+OE | $64.90 | -16,722 | 0 | -100% | -$1,085,305 | |||||
| D | 2020-11-20 | MRSN | Mersana Therapeutics, Inc. | Lowinger Timothy B | Chief Science, Tech. Officer | S - Sale+OE | $23.05 | -8,203 | 0 | -100% | -$189,079 | |||||
| DM | 2020-11-20 | XOMA | Xoma Corp | Burns Thomas M. | SVP, Finance, CFO | S - Sale+OE | $32.69 | -12,000 | 10,238 | -54% | -$392,308 | |||||
| DM | 2020-11-20 | XOMA | Xoma Corp | Neal James R | CEO | S - Sale+OE | $32.81 | -20,000 | 25,522 | -44% | -$656,184 | |||||
2020-11-20 | ADMP | Adamis Pharmaceuticals Corp | Marguglio David J. | SVP, Chief Business Officer | S - Sale | $0.40 | -35,000 | 293,148 | -11% | -$14,000 | ||||||
2020-11-20 | ADMP | Adamis Pharmaceuticals Corp | Hopkins Robert O | CFO | S - Sale | $0.41 | -35,000 | 254,810 | -12% | -$14,182 | ||||||
| D | 2020-11-19 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale+OE | $45.18 | -11,355 | 265,237 | -4% | -$513,019 | |||||
2020-11-24 | TFFP | Tff Pharmaceuticals, Inc. | Fletcher Aaron G.L. | Dir | P - Purchase | $15.13 | +5,000 | 100,000 | +5% | +$75,656 | ||||||
| M | 2020-11-23 | PHAS | Phasebio Pharmaceuticals Inc | Thorp Clay | Dir | P - Purchase | $3.60 | +5,000 | 22,943 | +28% | +$18,010 | |||||
2020-11-20 | GLSI | Greenwich Lifesciences, Inc. | McWilliams David | Dir | P - Purchase | $5.40 | +1,500 | 620,101 | 0% | +$8,100 | ||||||
2020-11-20 | GLSI | Greenwich Lifesciences, Inc. | Hallock Kenneth | Dir | P - Purchase | $5.37 | +1,000 | 396,004 | 0% | +$5,370 | ||||||
2020-11-20 | GLSI | Greenwich Lifesciences, Inc. | Rothe Eric | Dir | P - Purchase | $5.40 | +2,000 | 313,226 | +1% | +$10,800 | ||||||
| M | 2020-11-20 | QLGN | Qualigen Therapeutics, Inc. | Kruger Kurt H | Dir | P - Purchase | $3.48 | +6,000 | 6,000 | New | +$20,894 | |||||
2020-11-23 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Childs John W | Dir | P - Purchase | $89.55 | +5,000 | 2,526,938 | 0% | +$447,737 | ||||||
2020-11-20 | ONCS | Oncosec Medical Inc | Alpha Holdings, Inc. | Dir | S - Sale | $4.92 | -80,000 | 1,350,001 | -6% | -$393,872 | ||||||
2020-11-19 | CARA | Cara Therapeutics, Inc. | Posner Christopher | Dir | S - Sale | $15.82 | -2,000 | 11,200 | -15% | -$31,638 | ||||||
| M | 2020-11-19 | KDNY | Chinook Therapeutics, Inc. | Dobmeier Eric | Pres, CEO | P - Purchase | $13.63 | +2,000 | 52,837 | +4% | +$27,266 | |||||
2020-11-23 | PHAS | Phasebio Pharmaceuticals Inc | Burkhardt Glen | VP, HR | S - Sale | $3.45 | -3,497 | 0 | -100% | -$12,065 | ||||||
| M | 2020-11-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Bradshaw Curt | Chief Scientific Officer | S - Sale | $69.06 | -31,250 | 0 | -100% | -$2,158,125 | |||||
| D | 2020-11-19 | BMY | Bristol Myers Squibb Co | Vessey Rupert | EVP, Research, Early Dev. | S - Sale+OE | $61.30 | -57,591 | 51,956 | -53% | -$3,530,269 | |||||
2020-11-19 | PAND | Pandion Therapeutics, Inc. | Becker Daniel J. | Dir | P - Purchase | $15.12 | +197,716 | 2,827,883 | +8% | +$2,989,466 | ||||||
2020-11-19 | ALPN | Alpine Immune Sciences, Inc. | Conway Robert E | Dir | P - Purchase | $8.03 | +10,000 | 25,000 | +67% | +$80,300 | ||||||
| D | 2020-11-23 | OLMA | Olema Pharmaceuticals, Inc. | Cormorant Asset Management, LP | Former 10% Owner | P - Purchase | $19.00 | +425,000 | 3,270,544 | +15% | +$8,075,000 | |||||
| D | 2020-11-23 | OLMA | Olema Pharmaceuticals, Inc. | Graham G. Walmsley | Dir | P - Purchase | $19.00 | +1,160,000 | 1,160,000 | New | +$22,040,000 | |||||
2020-11-19 | SDGR | Schrodinger, Inc. | Brauner Shane | See Remarks | S - Sale | $57.46 | -5,000 | 28,867 | -15% | -$287,300 | ||||||
| D | 2020-11-19 | SDGR | Schrodinger, Inc. | Tran Yvonne | See Remarks | S - Sale+OE | $59.15 | -26,377 | 27,131 | -49% | -$1,560,256 | |||||
2020-11-20 | DMAC | Diamedica Therapeutics Inc. | Giuffre Randall Michael | Dir | P - Purchase | $4.26 | +15,000 | 189,009 | +9% | +$63,912 | ||||||
| D | 2020-11-19 | EYEN | Eyenovia, Inc. | Gandolfo John P | CFO | P - Purchase | $3.40 | +4,000 | 6,000 | +200% | +$13,600 | |||||
2020-11-19 | MATN | Mateon Therapeutics Inc | Park Chulho | CTO | P - Purchase | $0.18 | +22,173 | 2,833,992 | +1% | +$4,098 | ||||||
2020-11-19 | MATN | Mateon Therapeutics Inc | Trieu Vuong | CEO | P - Purchase | $0.19 | +50,500 | 19,944,035 | 0% | +$9,595 | ||||||
2020-11-19 | RAPT | Rapt Therapeutics, Inc. | Robbins Wendye | Dir | P - Purchase | $16.09 | +1,000 | 5,600 | +22% | +$16,085 | ||||||
| D | 2020-11-20 | SBPH | F-Star Therapeutics, Inc. | Winslow Garrett | GC, Secretary | S - Sale+OE | $4.76 | -175 | 18,575 | -1% | -$833 | |||||
| D | 2020-11-20 | SBPH | F-Star Therapeutics, Inc. | Driscoll Martin J | Pres, CEO | S - Sale+OE | $4.76 | -175 | 47,425 | 0% | -$833 | |||||
| D | 2020-11-20 | SBPH | F-Star Therapeutics, Inc. | Firmani Lori | VP of Finance, Treasurer | S - Sale+OE | $4.76 | -175 | 17,867 | -1% | -$833 | |||||
| D | 2020-11-20 | SBPH | F-Star Therapeutics, Inc. | Iyer Radhakrishnan P. | Chief Scientific Officer | S - Sale+OE | $4.76 | -175 | 137,637 | 0% | -$833 | |||||
| D | 2020-11-20 | ACAD | Acadia Pharmaceuticals Inc | Stankovic Srdjan R. | Pres | S - Sale+OE | $53.50 | -2,728 | 16,528 | -14% | -$145,948 | |||||
| D | 2020-11-18 | PLXP | Plx Pharma Inc. | Valentino Michael J | Exec COB | P - Purchase | $3.79 | +264,900 | 461,690 | +135% | +$1,003,176 | |||||
2020-11-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | San Martin Javier | Chief Medical Officer | S - Sale | $69.39 | -19,500 | 130,500 | -13% | -$1,353,105 | ||||||
2020-11-19 | ONCS | Oncosec Medical Inc | Alpha Holdings, Inc. | Dir | S - Sale | $5.10 | -50,000 | 1,430,001 | -3% | -$255,230 | ||||||
2020-11-19 | ZGNX | Zogenix, Inc. | Garner Cam L | Dir | P - Purchase | $20.13 | +8,000 | 56,843 | +16% | +$161,042 | ||||||
2020-11-18 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $4.13 | -162,473 | 530,199 | -23% | -$671,013 | ||||||
| M | 2020-11-18 | TYME | Tyme Technologies, Inc. | Hoffman Steve | CEO, 10% | S - Sale | $0.94 | -96,621 | 25,774,904 | 0% | -$90,824 | |||||
| D | 2020-11-18 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale+OE | $43.69 | -10,313 | 273,467 | -4% | -$450,579 | |||||
| D | 2020-11-19 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale+OE | $164.06 | -6,000 | 35,680 | -14% | -$984,360 | |||||
2020-11-18 | ADMP | Adamis Pharmaceuticals Corp | Moss Ronald B. | Chief Medical Officer | S - Sale | $0.41 | -8,532 | 231,752 | -4% | -$3,465 | ||||||
2020-11-18 | ADMP | Adamis Pharmaceuticals Corp | Hopkins Robert O | CFO | S - Sale | $0.41 | -7,229 | 289,810 | -2% | -$2,936 | ||||||
2020-11-18 | ADMP | Adamis Pharmaceuticals Corp | Carlo Dennis J Phd | Pres,amp; CEO | S - Sale | $0.41 | -10,665 | 472,997 | -2% | -$4,331 | ||||||
2020-11-18 | ADMP | Adamis Pharmaceuticals Corp | Daniels Karen K. | VP of Operations | S - Sale | $0.41 | -5,333 | 149,242 | -3% | -$2,166 | ||||||
2020-11-18 | ADMP | Adamis Pharmaceuticals Corp | Marguglio David J. | SVP, Chief Business Officer | S - Sale | $0.41 | -8,532 | 328,148 | -3% | -$3,465 | ||||||
| D | 2020-11-18 | YMAB | Y-Mabs Therapeutics, Inc. | Gill David N | Dir | S - Sale+OE | $45.77 | -2,000 | 0 | -100% | -$91,530 | |||||
| DM | 2020-11-18 | OPTN | Optinose, Inc. | Mahmoud Ramy A | Pres, COO | S - Sale+OE | $5.02 | -5,257 | 73,465 | -7% | -$26,366 | |||||
| DM | 2020-11-18 | OPTN | Optinose, Inc. | Miller Peter K | CEO | S - Sale+OE | $5.02 | -5,686 | 150,356 | -4% | -$28,538 | |||||
2020-11-19 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | S - Sale | $39.48 | -4,000 | 254,504 | -2% | -$157,920 | ||||||
| D | 2020-11-19 | ALNY | Alnylam Pharmaceuticals, Inc. | Maraganore John | CEO | S - Sale+OE | $124.23 | -34,765 | 200,722 | -15% | -$4,319,025 | |||||
2020-11-19 | RAPT | Rapt Therapeutics, Inc. | Rieflin William Jl | Dir | P - Purchase | $16.22 | +10,000 | 94,722 | +12% | +$162,200 | ||||||
2020-11-19 | XBIT | Xbiotech Inc. | McKenzie W Thorpe | Dir, 10% | S - Sale | $18.30 | -375,000 | 2,667,251 | -12% | -$6,862,500 | ||||||
2020-11-19 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO | P - Purchase | $5.40 | +2,000 | 7,779,758 | 0% | +$10,795 | ||||||
| M | 2020-11-17 | PAND | Pandion Therapeutics, Inc. | Becker Daniel J. | Dir | P - Purchase | $15.29 | +29,394 | 2,630,167 | +1% | +$449,400 | |||||
| D | 2020-11-17 | ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP, GC | S - Sale+OE | $27.62 | -79,425 | 0 | -100% | -$2,193,446 | |||||
2020-11-18 | CORT | Corcept Therapeutics Inc | Baker G Leonard Jr | Dir | P - Purchase | $17.91 | +2,372 | 5,155,678 | 0% | +$42,491 | ||||||
| M | 2020-11-17 | SDGR | Schrodinger, Inc. | Shaw David E | 10% | S - Sale | $59.07 | -381,026 | 10,994,668 | -3% | -$22,507,180 | |||||
| M | 2020-11-17 | ORGO | Organogenesis Holdings Inc. | Avista Capital Managing Member Iv, LLC | Dir, 10% | P - Purchase | $3.29 | +4,404,162 | 29,921,676 | +17% | +$14,500,672 | |||||
| DM | 2020-11-17 | MORF | Morphic Holding, Inc. | Tipirneni Praveen P. | Pres, CEO | S - Sale+OE | $30.09 | -6,099 | 645,960 | -1% | -$183,512 | |||||
| D | 2020-11-17 | MORF | Morphic Holding, Inc. | Devaul William | GC, Secretary | S - Sale+OE | $30.10 | -4,275 | 3,286 | -57% | -$128,673 | |||||
2020-11-17 | CARA | Cara Therapeutics, Inc. | Vogelbaum Martin | Dir | S - Sale | $16.09 | -6,000 | 14,400 | -29% | -$96,540 | ||||||
2020-11-17 | CARA | Cara Therapeutics, Inc. | Chalmers Derek T | Pres, CEO | S - Sale | $16.00 | -11,799 | 941,421 | -1% | -$188,784 | ||||||
2020-11-17 | ORGO | Organogenesis Holdings Inc. | Katz Michael W | 10% | P - Purchase | $3.25 | +20,829 | 34,432 | +153% | +$67,694 | ||||||
| D | 2020-11-17 | SDGR | Schrodinger, Inc. | D'Cruz Cony | See Remarks | S - Sale+OE | $60.69 | -6,375 | 171,082 | -4% | -$386,899 | |||||
2020-11-17 | ORGO | Organogenesis Holdings Inc. | Mackie Wayne D | Dir | P - Purchase | $3.25 | +42,726 | 161,290 | +36% | +$138,860 | ||||||
2020-11-17 | ORGO | Organogenesis Holdings Inc. | Leibowitz Arthur S | Dir | P - Purchase | $3.25 | +6,943 | 30,507 | +29% | +$22,565 | ||||||
| D | 2020-11-17 | MYOV | Myovant Sciences Ltd. | Karbe Frank | Principal Fin'l, Accounting | S - Sale+OE | $20.00 | -750 | 163,470 | 0% | -$15,000 | |||||
| D | 2020-11-17 | MYOV | Myovant Sciences Ltd. | Arjona Ferreira Juan Camilo | Chief Medical Officer | S - Sale+OE | $20.00 | -7,000 | 138,026 | -5% | -$140,000 | |||||
2020-11-18 | ONCS | Oncosec Medical Inc | Alpha Holdings, Inc. | Dir | S - Sale | $5.24 | -50,999 | 2,971,001 | -2% | -$267,316 | ||||||
2020-11-17 | ORGO | Organogenesis Holdings Inc. | Nussdorf Glenn H | Dir, 10% | P - Purchase | $3.25 | +833,153 | 137,242,799 | +1% | +$2,707,747 | ||||||
2020-11-18 | GTHX | G1 Therapeutics, Inc. | Muir Glenn P | Dir | P - Purchase | $13.50 | +50,000 | 170,969 | +41% | +$675,000 | ||||||
2020-11-17 | KROS | Keros Therapeutics, Inc. | Nussbaum Ran | Dir, 10% | P - Purchase | $50.00 | +60,000 | 155,262 | +63% | +$3,000,000 | ||||||
2020-11-17 | KROS | Keros Therapeutics, Inc. | Kariv Tomer | Dir, 10% | P - Purchase | $50.00 | +60,000 | 155,262 | +63% | +$3,000,000 | ||||||
2020-11-17 | KROS | Keros Therapeutics, Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 10% | P - Purchase | $50.00 | +60,000 | 155,262 | +63% | +$3,000,000 | ||||||
2020-11-16 | DFFN | Diffusion Pharmaceuticals Inc. | Cobuzzi Robert Joseph Jr. | Pres, CEO | P - Purchase | $0.66 | +14,000 | 14,000 | New | +$9,240 | ||||||
| D | 2020-11-16 | BBIO | Bridgebio Pharma, Inc. | Henderson Michael Thomas | Chief Business Officer | S - Sale+OE | $45.00 | -10,000 | 274,211 | -4% | -$450,000 | |||||
2020-11-16 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $16.93 | -29,618 | 266,697 | -10% | -$501,433 | ||||||
2020-11-16 | NKTR | Nektar Therapeutics | Wilson Mark Andrew | SVP, GC | S - Sale | $16.93 | -1,539 | 49,850 | -3% | -$26,055 | ||||||
2020-11-16 | NKTR | Nektar Therapeutics | Thomsen Jillian B. | SVP, Chief Accounting Officer | S - Sale | $16.93 | -11,976 | 159,757 | -7% | -$202,754 | ||||||
2020-11-16 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $0.93 | -20,000 | 25,118,546 | 0% | -$18,696 | ||||||
2020-11-16 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $16.93 | -11,975 | 352,453 | -3% | -$202,737 | ||||||
2020-11-16 | NKTR | Nektar Therapeutics | Labrucherie Gil M | SVP, COO, CFO | S - Sale | $16.93 | -8,276 | 226,973 | -4% | -$140,113 | ||||||
| M | 2020-11-16 | TZAC | Tenzing Acquisition Corp. | Glazer Capital, LLC | 10% | S - Sale | $10.90 | -1,328 | 648,666 | 0% | -$14,475 | |||||
| D | 2020-11-17 | BCEL | Atreca, Inc. | Greenberg Norman Michael | Chief Scientific Officer | S - Sale+OE | $15.04 | -1,825 | 0 | -100% | -$27,448 | |||||
2020-11-17 | EVFM | Evofem Biosciences, Inc. | File Justin J. | CFO | P - Purchase | $2.17 | +7,760 | 258,168 | +3% | +$16,839 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |